Lapatinib is the first TKI targeting HER2 to be approved that reversibly competes with adenosine triphosphate for its binding site on the tyrosine kinase domain and inhibits downstream pathways and tumor cell proliferation [15]. Here, ERBB2 is linked to neoplasm.